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policies for device utilization and future development however, it is impera- 
tive to describe the charsctedstice of these patients. To this end, we studied 
the age at initial implant for 35,533 patients who underwent ICD surgery in the 
v ~ from 1 ~oc , , e~ ~ ~ . . . . .  ~ ,  '!~!'~,~,'~ f~rim CPI1 tho on!v m:'mufaCttlrc~r 
with an ~-u,~-al~p=~ ~ . . . . . .  ~ c ~,~ urtttl 19~3. 
Result: During this time period, mean age at initial ICD implant increased 
from 60.0 yrs to 63.4 yrs. Regression analysis howed an average increase 
in age at implant of 140 days/yr (p -~ 0.001). Although the overall mean age 
for females was lower than for males (60 ± 12.6 yrs vs. 62.5 ± 10.6 yrs, p 
< 0.001), there was no difference in the average increase in age for each 
year of observation. The proportion of pts of Medicare-eligible age (>_ 65 yr) 
increased from 39% in 1986 to 53% in 1994 (p < 0.001). The US population 
>_. 65 yrs old, increased from 12.1% to 12.8% over the same time period. 
Conclusions: I) Future public policy decisions regarding Medicare funding 
of devices and other invastigationat medical procedures must consider the 
Increasing age of recipients of that technology. 2) Specifically for ICD, our 
find;ngs uggest hat by the year 2000, two-thirds of all patients receiving an 
ICD will be of Medicare age. 
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~High  Rate Silent Cerebral Infarction Annual Event of 
in Patients With Nonvalvular Atrial Fibrillation 
Yukihiro Koretsune, Masatsugu Hod, Takenobu Kamada, The First 
Department of Medicine, Osaka, Japan; Osaka University School of 
Medicine, Osaka, Japan; COOPAT (Cooperative Osaka Platelet 
Antiaggregation Trial) STUDY GROUP, Osaka, Japan 
Nonvalvular atrial fibrillation (NVAF) increases the risk of stroke almost six 
fold, however, the incidence of silent cerebral infarction (SCI) is unclear. 
To study the annual event rate of SCI in patients with NVAF, 100 patients 
(68 male, 32 female; 59 continuous, 41 paroxysmal; age, 62.0 :E 1.0, mean 
± SEE) without history of cerebrovascular ccident underwent clinical eval- 
uation, ECG, 2D and M mode Echo/Dopptsr-cardiogrsphy. Brain magnetic 
resonance imagings (MRI, T1- and T2-weighted, and Proton images) were 
determined twice with 12 months interval. None of these patients had re- 
ceived anticoagulant or antiplatelet therapy. Percent fractional shortening of 
left vemricular wall was ,98 ± 5.5%. SCI were detected in 84% of patients (age 
50': 70','°, 60': 95%, 70': 100%) in the initial MRI. There was no significant 
difference in the prevalence of SCI between paroxysmal nd continuous At. 
The average number of infarcted foci was 31.1 ± 5.5 (range: 0 to 193) per 
patient. Dudng a follow-up of 12 months, the rate of SCI was 25% per year. 
Locations of new infarcted foct were in the white-matter (12°/,,), the deep 
white-matter (60%), basal ganglion (28%), thalamus (4"/0) and brain stem 
(12°/o). 
Thus, we conclude that the annual event rate of SCI is quite common in 
patients with NVAF. 
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~ Lipoprotein(a) as a Determinant of CHD in Younger 
Women 
Kdstina Odh-Gom~r, Murray A. Mittleman, Kadn Schenck-Gustafsson, 
tars Ryd(~n. Karolincka Institute, Stockholm, Sweden; Karolinska Hospital, 
Stockholm, Sweden; Institute for Prevention of Cardiovascular Disease, 
Boston, MA; Deaconess Hospital, Boston, MA 
Lp(a) appears to be a dsk factor for CHD in men. However the role of 
Lp(a) In women is less clear. We examined the ability of Lp(a) to predict 
DHD in a popolation-besed case-control study of women aged 65 or under, 
living in the greater Stockholm area. Cases were all patients hospitalized 
for an acute CHD event between Feb. 1991 and Feb. 1994. Controls were 
randomly selected from the city census and were matched to cases by age 
end catchment area. Lp(a) was measured using an immunoturbidomatric 
method (Incstar) calibrated to the Northwest Lipid Research Laboratories 
(CV < 9%), 
Of the 292 consecutive cases, 109 (37%) were hospitalized for an acute 
MI and 182 (63%0) for angina pectoris. The mean age in both groups was 56 
± 7 years. 74 patients (25%,) and 84 controls (29%) were prsmenopausal. 
The distflbutions of Lp(a) were highly skewed in both cases and controls 
with a r'lnge from 0.1 to 114 mg/dl. Age-adjusted odds ratios for CHD in the 
highest versus the lowest quartile of Lp(a) was 2,1 (95% CI 1.1,3.4). Adjusting 
for age, smoking, education, body mass index, systolic blood pressure, total 
cholesterol, triglyceddes, and HDL, the odds ratio was 2.6 (95% CI 1.5, 4.4), 
The odds ratios were similar when cempedng MI and angina patients with 
their respective controls. The odds ratios were 4.3 (95% Cl 1.2, 15.1), and 
2.3 (95% 1,2, 4,2) in pre and postmenopausal women respectively. 
These results uggest hat Lp(a) is a determinant of CHD in both pre and 
postmenopaucal women. 
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~ '~-7  Do We Undertrest Hyperlipidemia? The Use of 
Lipid-Lowerlng Agents in Patients With Coronary 
Ar~ ~lseas~ 
Todd B. Sate, Mary Ann Tremble, Geoffrey S. Ginsburg. Beth Israel 
Hospital, Boston,/VIA; Harvard Medical School, Boston, MA 
Background: Evidence suggests that lipid-lowering medications decrease 
mortality in patients (pts) with coronary artery disease (CAD) and hypedipi- 
demia; it has been suggested that LDL be the target of therapy with the 
goal < 100 mg/dL. The purpose of this study was to estimate how frequently 
pts with CAD and hypedipidemia are prescdbed lipid-lowering medications 
and achieve target LDL in clinical practice. Methods: We prospectively iden- 
tified pts with known CAD electively admitted to the intermediate cardiac 
care service at an urban, university affiliated hospital. All pts were cared for 
by a cardiologist. Fasting lipid profiles were tested on admission. Results: 
Fifty-two pts were studied (mean age(sd) 61(15)yr; 77% male; 96% admitted 
for angiography and/or revascutsrization; 71% hypertensive; 27°/, diabetic). 
Eighty-one percent had LDL > 100 mg/dL, of whom 31% were on lipid- 
iowedng agents. In contrast, 100%o with hypertension (p < 0.0001) and 92=/0 
of diabetics (p < 0.0001) received medical therapy for those dsk factors, and 
98'/= were on aspidn (p = 0.0001). Of all pts on lipid-lowedng agents, only 
38% had achieved target LDL _< 100 rag/alL. HMG-CoA reductase tnhibitors 
were more commonly prescribed (25%) than all other lipid agents combined. 
Of all pts, only 6% were at target LDL _< 100 mg/dL with dietary therapy alone. 
Conclusion: We conclude that 1) The majority of pts eligible for lipid-lowering 
agents do not receive it; 2) For pts who receive therapy, the suggested target 
LDL is often not attained; 3) Hypertension and diabetes are treated much 
more frequently than hyperlipidemla. 
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F7"~-5-] Undertrestment of Dyelipidemia in Veterans W'dh 
Coronary Artery D isease- -  Fol lowup After 
NCEP:ATP II 
Nancy A. Downey, Edward Lee, James M. Sampsel, Geeta Sikand, Moti 
L Kashyap, James M. Hag°r, The CREATE Study; Cardiology Section and 
Cholesterol Center. Long Beach VAMC, Long Beach, CA; University of 
California,/wine 
The National Cholesterol Education Program: ATP II (NCEP) has established 
new aggressive goals for lipid treatment in patients with coronary artery 
disease (CAD), which reduces recurrent CAD events in clinical trials. It 
is unknown how often these goals are actually achieved in the pdmary 
care setting, or whether these guidelines have influenced treatment. We 
studied 1,934 veterans with known CAD having lipid testing between 1991- 
93 and followed for 22.3 ± 10.2 (mean ± so) months, 1 year after release of 
NCEP:ATP II guidelines. Dyslipldemla (LDL > 130, TG > 200, or HDL < 35) 
was initially present in 1580 patients (82%). Mean LDL was 144 ± 48, total 
cholasteml 216 ± 46, and HDL 40 :E 16 mg/dL In 61% LDL was • 130, the 
previous NCEP target. At followup 34% of patients failed to meet he revised 
NCEP target (LDL < 100) and 59% had an LDL > 130. Mean followup lipids 
were unchanged from initial values. A mean of 4.5 -t- 3.7 lipid profiles were 
drawn per patient. Lipid-lowedng drugs were used in 32%0, but these patients 
did not reach LDL goal any more often than those not on drugs, Reasons for 
not achieving a LDL < 100 were failure to use lipid drugs (37%), inadequate 
dose and/or bose-limiting side effects when drugs were used (24%), and 
failure to retest lipide (2L~o). 
Needy all in this high dsk population have dyslipidernia requldng Interven- 
tion by NCEP cdteda; few reach target LDL levels, and lipid treatment did not 
improve after 2 year followup, Substantial cost and effort are expended in 
testing and attempting to treat dyslipidemic CAD patients in the primary care 
setting, but fail to achieve optimum lipid lowering. More effective treatment 
strategies must be implemented before the benefits of lipid Iowedng can be 
achieved outside of clinical trials. 
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~91"~ Acute Contrast Nephropsthy After Coronary 
Intervention: Incidence, Risk Factors, and 
Relationship to Mortality 
Peter A. McCullough, Robert Wolyn, Leslie L. Rocher, Robert N. Levin, 
William W. O'Neill. William Beaumont Hospital, Royal Oak, Michigan 
Previous studies of contrast naphropathy have identified reduced baseline 
renal function, diabetes, congestive heart failure, and contrast volume as 
risk factors for renal failure post-artedography. The reported incidences of a 
rise In serum creatinine and renal failure requiring dialysis vary widely. The 
relationships between these events and mortality am not well understood. 
This retrospective cohort study of 1828 patients included all interventional 
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coronary angingraphy performed from 12/93 to 8/94 at our institution. The 
Inc ide~ of 25% rise in serum creatinine was 145/1000 cases and the 
incidence of renal failure requiring dialysis was 8/10~0 cases. The cutoff 
dose of contrast below which there were no dialysis cases was 100 ml. 
No patient with a baseline calculated creatinine clearance (CrCI, Cockcroft- 
Gault method) above 47 ml/min developed renal failure requiring dialysis. 
Multivariate analyses revealed baseline CrCI (OR = 0.85, 95% CI 0.80-0.90, 
p < 0.00001), diabetes (OR = 5.12, 95% CI 1.37-19.22, p = 0.16), and 
contrast dose (OR = 1.006, 95% CI 0.999-1.011, p = 0.053) as predictors of 
dialysis. The significant, independent relationships between severity of renal 
failure and case-mortality rate are shown below. 
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Conclusions: 1) The rate of renal failure requiting dialysis after coronary 
intervention is 0.8%. 2) A minimum CrCI of 47 mVml or a maximal contrast 
dosage of 100 mi may be thresholds beyond which eedous renal failure 
can occur. 3) Baseline creatinine clearance, diabetes, and contrast dose 
are important independent predictors of contrast nephropathy. 4) Contrast 
nephropathy, especially in those cases requiring dialysis, is strongly associ- 
ated with high (33.3%) in-hospital mortality. 
Is IVUS Necessary for Optimal Stent 
Deployment? 
Wednesday, March 27, 1996, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Room 315 
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~ 7  High-Pressure Inflations Do Not Insure 'Adequate' 
Stent Deployment: E~tidence From Intravascular 
Ultrasound 
Anthony C. De Franco, E. Murat Tuzcu, Khaled M. Ziada, Nirav Shah, 
Seilash Babu, A. Michael Lincoff, Russell Raymond, Patrick L. Whitlow, 
Stephen G. Ellis, Steven E. Nissen. Cleveland Clinic OH 
Background: Intmvascular ultrasound cdtsria for adequate stent deployment 
require a minimum cross-sectional area, typically > 70-80%o of an adjacent 
reference site. However, the morphology and procedural factors associated 
with failure to fully expand are uncertain. 
Methods: A core laboratory measured lumen diameter and area, plaque 
thickness and area, as well as percent area reduction. Inadequate expansion 
was defined as any segment < 70% of the area of the mean proximal and 
distal reference segments by ultrasound. 
Results: Of 74 stents, 13 (17.5%) had inadequate xpansion at a time when 
the angio~lram suggested procedural completion. There were no significant 
differences between the two groups in anglagraphic vessel size (mean, 3.12 
vs 3,23 ram), maximum balloon pressure (mean, 17,3 vs. 16.4 atm), inflation 
time, pre-procedural lesion severity, or ACC/AHA lesion score. Patients with 
inadequate deployment were treated with additional inflations, wadadn, or 
both). 
Post-stent Measurements Adequate Inadequate p 
Ultrasound Reference Size (ram) 3.34 3.50 0.05 
Mean Plaque Thickness (mm) 0.69 0.g5 0.004 
Anglo Final Stenosis (%) -2.3% +4.7% 0.03 
Ultrasound Area Reduction (%) 53.5 64.1 0.003 
Anglo Baltoon/Re terence Ratio 1.17 1.13 NS 
Ultrasound Balloon/Reference Ratio 1.15 1.02 0.003 
C¢nclusions: Despite "high-pressure" stent technique, 17% fail to achieve 
a typical cdtedon for adequate expansion, usually in segments with a heavy 
plaque burden and/or a low balloon-to-vessel size ratio calculated by ultra- 
sound (but not angiography). Thus: 1) Angiography alone may be insufficient 
to determine which patients can forego warfarin, 2) Ultrasound identifies pa- 
tients who may benefit from pre-stent debulking and/or additional inflations 
with a larger balloon. 
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Can Quantitative Coronary  Analysis Replace 
Inlravascular Ultrasound to As=,o~ Optimal Stent 
Deployment? 
Luc eiloOeau, Serge Doucet, Gilles CatS, dean-Claude Tardif, Raoul 
Bonan Olivier, F. Bertrand. Montreal Heart Institute, Montreal, Canada 
The accepted IVUS criteria of optimal stent deployment are: complete ap- 
position, symmeW index > 0.7, and minimum inner stent area > than the 
distal reference area as well as > than 96=/0 average reference area. To 
define angiographic critsda of optimal stent deployment we reviewed an- 
giograms of 35 stsnts implanted under IVUS guidance (HP ~ 30 mHz). All 
angiograms were analysed by quantitative cumnary analysis (CMS system). 
The deployment of the stents analysed was defined as optimal (n = 25) or 
non optimal (N = 27) according to the above mentioned IVUS criteria. Using 
the best angiagraphic view, the diameter of the proximal and distal reference 
segments were measured. The stent measurements included the minimum, 
maximum and mean inner diameters. The ratios between the inner stent di- 
ametere and the mean proximal, distal and interpolated reference diameters 
were calculated. 
! 
Receiver operating characteristic (ROC) curves were used to evaluate 
the performance of these d~emnt ratios. None of the tested angingraphtc 
parameters and ratios could predict adequate stent deployment. Thus IVUS 
still remains the most discriminating tool to assess stent deployment. 
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~- ' ]  Is Quantitative Angiography a Surrogate of 
Intrevascelar Ultrasound for Guidance of Stem 
Deployment? A Compar ison With 3-D Quanti tat ive 
Reconstruction of  Intracoronary Ultrasound 
Francesco Prati, Cado Di Mado, Robert Git, Edoardo Camenzind, 
Clemens yon eirgelen, Eiine Van Swijndregt, Patrick W. Serruys. 
Thoraxcenter, Erasmus University, Rotterdam, The Netherlands 
Aim of this study was to assess the usefulness of quantitative coronary an- 
gingraphy for the evaluation of optimal stent expansion, confirmed with a 
new on-line system of three-dimensional reconstruction of intravescular ul- 
basound (IVUS). Seventy 5tsnts (31 Palmaz-Schalz, 22 Wallstent, 7 Cordis, 
6 Micro-stent, 2 Gianturcu-Roubin, 2 Multi-link) were imaged in 49 patients 
with 3-D IVUS. IVUS assessment was performed after achievement of an 
optimal on-line quantitative cumnary angiography (QCA) result, defined as 
negative percent diameter stenosis (stent MLD/user defined reference diam- 
eter). QCA percentage diameter stenosis was also calculated off-line with 
a "stent analysis" approach, limited to the stented part of the vessel sng- 
menL as the ratio stent MLD/interpolated reference diameter. IVUS images 
of stents and adjacent proximal and distal reference segments were acquired 
using a motorized pull-bank at a constant speed (1 ram/s) and immediately 
processed in the catheterization laboratory using an automated contour de- 
tection algorithm based on acoustic quantification. IVUS criteria indicative of 
optimal stent expansion were: 1 ) complete appos~on of stent struts to vessel 
wall; 2) minimal stent lumen area greater or equal to 80% of the average 
lumen area of the proximal and distal reference segments. 
Results: Comparison of QCA and 3-D IVUS measurements are reported 
in the table. 
On-line QCA Off -Itne QCA 3-D IVUS 
Vessel analysis Intrestent a alysis 
Stent MLD 2.7 =l: 0.4 2.7 4. 0.4* 3.0 4. 0.5 
% Area Stenosis -5.1 4. 8.4%* 9.5 4. 5.0%* 24 :t: 6.1% 
Legend. MLD = Minimal lumen diameter, *p < 0.01 
3-D IVUS cfitefla of adequate stent expansion were achieved only in 30 
out of 70 stsnts (43%). By using a QCA "stent analysis" approach it was 
found that a 10% diameter stenosis cut-off value revealed adequate stent 
expansion with high specificity (86%). Conclusions: 3-D IVUS criteda of 
adequate stent expansion are achieved only in 43% of patients despite the 
